Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Figures & data

Table 1 Sociodemographic and clinical characteristics of participants

	Olz (n=35)	Quet (n=29)	HC (n=32)	Statistics
Age (years)	38 (22–55)	42 (20–58)	35 (28–45)	df =2, P=0.078
Sex
Female	20 (57.1%)	15 (51.7%)	11(34.4%)	χ^2 =3.71, P=0.156
Male	15 (42.9%)	14 (48.3%)	21 (65.6%)
Smoking
Yes	18 (51.4%)	12 (41.4%)	17 (53.1%)	χ^2 =0.91, P=0.61
No	17 (48.6%)	17 (58.6%)	15 (46.9%)
TC (mg/dL)	194 (142–293)	172.5 (102–235)	188.5 (103–220)	df =2, P=0.042 Olz and Quet: P=0.04 Olz and HC: P=0.02 Quet and HC: P=0.71
TG (mg/dL)	166.7 (48–389)	161.1 (42–298)	159.3 (89–242)	df =2, P=0.88
LDL-C (mg/dL)	129.4 ± 34.44	108 ± 29.19	110.78 ± 30.59	F =8.92, P=0.038 Olz and Quet: P=0.03 Olz and HC: P=0.04 Quet and HC: P=0.81
HDL-C (mg/dL)	36 (24–57)	39.5 (30–51)	40 (27–56)	df =2, P=0.472
BMI (kg/m^2)	23.44 ± 1.67	23.41 ± 0.68	23.21 ± 0.77	F =0.92, P=0.4
Daily dose (mg)*	265.71 ± 87.26	683.91 ± 155.48	–	t =−13.56, P<0.01

Notes:

* Represents chlorpromazine-equivalent dose. Significant differences between groups are highlighted in bold. Age, TC, and HDL-C are represented as median (range); TG, LDL-C, BMI, and Daily dose are represented as mean ± standard deviation.

Abbreviations: BMI, body mass index; HC, healthy control; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Olz, olanzapine group; Quet, quetiapine group; TC, total cholesterol; TG, triglyceride.

Table 2 Serum PON1 activity, serum TAOP and TPEROX levels, and status of OSI in the olanzapine, quetiapine, and HC groups

	Olz (n=35)	Quet (n=29)	HC (n=32)	Statistics
PON1 (U/L)	93 (42–294)	156 (40–529)	156.5 (56–520)	df =2, P=0.008 Olz and Quet: P=0.014 Olz and HC: P=0.04 Quet and HC: P=0.91
TAOP (mmol trolox equivalent/L)	1.95 ± 0.23	2.05 ± 0.33	2.06 ± 0.29	F =1.57, P=0.21
TPEROX (mmol H2O2 equivalent/L)	6.51 ± 2.11	6.93 ± 3.7	6.57 ± 2.29	F =0.20, P=0.81
OSI (TPEROX mmol H2O2 equivalent/L)/(TAOP mmol trolox equivalent/L)	0.34 ± 0.11	0.33 ± 0.14	0.32 ± 0.11	F =0.12, P=0.88

Notes: Significant difference between groups is highlighted in bold. PON1 is presented as median (range); TAOP, TPREOX, and OSI are presented as mean ± standard deviation.

Abbreviations: H₂O₂, hydrogen peroxide; HC, healthy control; Olz, olanzapine group; OSI, oxidative stress index; PON1, paraoxonase 1; Quet, quetiapine group; TAOP, total antioxidant potentials; TPEROX, total peroxide level.

Table 3 Correlation coefficients between scores of PON1 and age, sex, TC, TG, LDL-C, HDL-C, and smoking status in olanzapine, quetiapine, and HC groups

PON1	Age	Sex	TC	TG	LDL-C	HDL-C	Smoking
Olz	−0.199	−0.132	0.24	−0.088	−0.129	0.342	0.178
Quet	0.294	−0.04	0.178	0.099	−0.163	0.207	−0.201
HC	0.043	0.082	0.122	−0.106	−0.085	−0.034	−0.058

Note: Significant P-values predicted in bold.

Abbreviations: HC, healthy control; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Olz, olanzapine group; PON1, paraoxonase 1; Quet, quetiapine group; TC, total cholesterol; TG, triglyceride.